Haemonetics enters a fresh fiscal year as a blood management franchise in mid reinvention, pairing a plasma collection business with sticky razor-razorblade economics against a hospital portfolio whose operating profit roughly doubled across the past two fiscal years. The core thesis holds that the newly signed CSL Plasma supply accord restores a lapsed anchor account to the installed base, Persona PLUS yield technology extends the company's collection advantage, and disciplined repurchase activity compounds per-share economics while management deleverages. The question for shareholders is whether that rebalancing outruns customer concentration, the leverage stack, and the aftershock of an ablation market that turned against one acquired product line.
The signature event arrived on August 14, 2026, when management disclosed a supply agreement that reopens the CSL Plasma account to NexSys PCS devices with Persona PLUS technology and the matching disposables. That pact hands a defecting anchor customer a path back onto the current-generation installed base. The defection, negotiated before fiscal 2026 began, stripped a large block of nonrecurring revenue out of the prior-year comparison and forced margin repair through portfolio pruning. Pulling the account back at this stage would make the conversion spending of past years relevant again rather than sunk cost. The agreement avoids minimum purchase commitments and leaves the fiscal 2027 outlook untouched pending a proper quarterly update. Management kept the guidance unchanged precisely because conversion timing is the customer's choice, an approach that preserves credibility by refusing to book enthusiasm as revenue.
The tension sits in concentration and in the drifting economics of esophageal protection. Customer concentration frames the risk, because ten accounts supplied nearly half of fiscal 2026 revenue and the largest single plasma buyer contributed a mid-teens slice of sales on its own. Pulse field ablation, a tissue-selective alternative in cardiac ablation, compressed the addressable market for the ensoETM cooling device behind the Attune Medical purchase and pushed management into a $77.2 million intangible impairment in the closing quarter of the fiscal year. The impairment, harsh as it reads, converted a slow earnings bleed into a one-time accounting event and frees the narrative from a forecast that the market had already repriced.
Catalysts cluster across the next two quarters. Management expects to quantify the CSL agreement's effect on its fiscal 2027 outlook at the second-quarter report in November, and a domestic approval decision on PerQseal Elite sits inside the pipeline window over that same stretch. Buyback capacity near $325.0 million remains authorized, and the redemption logic behind the convertible notes activates near mid-2027 when the required price premium holds. The rhythm of updates over that window is where the thesis earns or loses its next round of support. Each update lands on a stretch of calendar where the defecting-customer repair, the regulatory pipeline and the capital return program all report at once, so the information density of the next two quarters stands well above the norm for a company of this size.
Haemonetics builds, sells and services blood management technology across roughly ninety countries from a Boston headquarters, organized since early June 2026 into two global reportable segments named Apheresis and MedSurg. The older three-segment picture layered a Plasma franchise running automated collection devices, donor management software and center workflow platforms over a Blood Center unit selling blood collection and processing hardware, with the Hospital segment carrying both interventional cardiology tools and operating room blood management technologies. That legacy structure had hidden the divergence between the growing hospital lines and the contracting collection lines, and the realignment makes the divergence itself the organizing principle of reporting. The June realignment pulled plasma and blood center operations together under Apheresis and renamed the hospital business MedSurg, a structure that mirrors how the chief executive now allocates resources and reads operating income. The realignment also quietly signals the destination, since a two-segment world reads as a company defined by its collection franchise and its clinical technology business rather than by the blood center legacy that once anchored it.
The strategic story of the past two fiscal years is a deliberate rotation of capital away from stagnant collection markets and toward hospital interventional growth. Management sold the Whole Blood product line to GVS, closing a California plant in the bargain and shrinking the unit that sells into declining transfusion markets. The divestiture, completed in January 2025, carried upfront cash plus a sales-contingent earnout on the divested assets. The same period brought two hospital acquisitions stacked on the earlier OpSens purchase, first Attune Medical for esophageal protection and then Vivasure Medical for large bore vessel closure in early 2026. Each purchase bought a technology platform in a procedure market with visible volume growth, which is the pattern the whole capital rotation follows, and the earlier minority stake in Vivasure gave management a two-year look at the asset before committing full price.
Hospital operations have become the growth engine both in mix and in profit, with the segment's operating profit roughly doubling across two fiscal years while its revenue share climbed about nine points. Plasma held its role as the profit engine with a margin near the mid-thirties, a level few medtech franchises match on comparable revenue. The pivot explains the fiscal 2026 top line decline, which conceals portfolio turnover large enough to reset the revenue base. Gross margin still expanded by five hundred basis points as high margin hospital product replaced legacy volume. The margin expansion is the quiet proof of the rotation, because a mix shift of that size arriving in the same year as a customer loss means the retained business carries structurally better economics than the business that left.
The concentration profile frames every strategic decision. Ten customers supplied roughly two fifths of fiscal 2026 revenue, a dependence that made the lapse with CSL Plasma so painful and its repair so valuable. The single largest plasma account contributed a mid-teens share of company sales on its own. Selling through direct teams and distributors spreads the geographic base, but the buyer universe at the top of the plasma market stays narrow by industry structure, since a handful of vertically integrated fractionators operate most dedicated collection networks. The company sits large in that small world of scale plasma collectors, and the United States supplies the large majority of global source plasma because collection regulations there favor frequency, volume and donor compensation.
The plasma franchise rests on a device-plus-software-plus-consumable stack that competitors struggle to replicate in one piece. NexSys PCS anchors the hardware, connecting bi-directionally to the NexLynk DMS donor management platform and Donor360 tools that automate donor interviews, qualification and unit release across a collection network. Yield enhancement rides on two proprietary approaches. YES technology lifts plasma per donation by an additional band of roughly twenty to twenty-five milliliters on average, based on data the company discloses in its product clearances. The software layer is the second half of the moat, because donor management platforms built over three decades hold the center workflow, the compliance record and the yield data that a competing device vendor would need years to match.
Persona PLUS is the fresh step function. Cleared in the fourth quarter of fiscal 2026, the next-generation nomogram delivers a mid single digit percentage increase in plasma per donation on top of Persona, extending a patent and regulatory moat that took years of clinical work and submissions to assemble. Conversion of United States customers onto Express Plus and Persona technologies completed by the end of fiscal 2026, which means the installed base is now standardized on current-generation hardware and the CSL agreement is the first large scale test of pulling a defected account back onto that base. Standardization also simplifies the sales pitch, since every United States evaluator can reference the same reference configuration rather than a patchwork of legacy software builds. A defector looking back at that standardized base sees a different product than the one it left, which is precisely the sales narrative the current agreement lets the company run. Every increment of yield per donation flows straight to fractionator economics, which is why yield claims carry such pricing power in this niche.
Hospital moats look different in each product line. VASCADE vascular closure devices hold Class III approvals built on randomized clinical evidence, and the MVP variant carries an FDA indication for same-day discharge after atrial fibrillation ablation, a workflow claim competitors lack. The fiscal 2026 label expansion for VASCADE MVP XL opened the device to procedures using larger sheaths deployed by market-leading pulsed field ablation and left atrial appendage closure platforms, repositioning the product precisely where ablation volume is accelerating. PerQseal Elite, acquired with Vivasure, seals large bore arteriotomies with a fully bioabsorbable patch from inside the vessel, targets structural heart procedures such as transcatheter valve replacement, and awaits a premarket approval decision in the United States while selling under CE Mark in Europe. The strategic logic is that structural heart procedure volumes keep climbing as populations age, and closure failures at the access site are the complication hospitals most want to engineer out of those cases.
Blood management rounds out the moat map. The TEG 6s viscoelastic analyzer leads the global advanced hemostasis testing segment, guiding transfusion decisions in cardiovascular surgery, trauma and transplant settings, and a heparinized-assay cartridge cleared in fiscal 2024 extended reach into cardiovascular procedures on full anticoagulation. Cell Saver autotransfusion and the SafeTrace Tx and BloodTrack software stack round out a line with entrenched hospital workflow positions. Switching costs run through clinician training, value analysis committee approvals and hospital information system integration, friction that protects share once a device or system enters daily use. The defense has held in the segments closest to the clinical workflow, where the TEG platform and the transfusion software stack gained share in the most recent quarter, while the product lines facing procedural transition rather than workflow entrenchment are exactly the ones that lost ground.
The fiscal 2026 income statement reads as a year of portfolio surgery rather than demand failure. Net revenues slipped two percent to $1,334.0 million while gross profit rose five percent to $787.6 million. Gross margin jumped four points to 59 percent in a single year, the sharpest single-year expansion in the reported history of this franchise mix, and the shift reflects portfolio composition rather than price repair. A mix-driven step of that size is more durable than a pricing cycle, because it is built from what the company sells rather than from what customers tolerate paying. Reported operating income fell by more than a quarter to $156.7 million, though the culprit is impairment accounting rather than operations or demand. The distinction between headline and underlying profit is the single most important reading skill for this fiscal year. Everything a reader needs to judge the enterprise sits in that gap, because the charges located the failed bets, while the segment tables locate the living franchises, and the two together map exactly where the next management dollar should flow. Segment operating profit tells the cleaner story, with plasma near $184.8 million and hospital at $103.7 million.
The bridge underneath tells the cleaner story. Blood management technologies rose almost fifteen percent on hemostasis and transfusion gains while interventional technologies fell as the esophageal franchise deflated. Blood center revenue dropped fifteen percent, and nearly all of that decline is the Whole Blood divestiture, since the residual apheresis line actually grew. Plasma lost modestly on the CSL transition, yet still gained share and price elsewhere in the mix, which speaks to the durability of the remaining accounts. The mix story matters more than the headline, because revenue that survives a titanic customer departure with only a two percent dent is revenue with genuinely durable demand behind it.
Cash dynamics were the quiet triumph of the year. Operating cash flow jumped by more than $110.0 million year over year, while capital expenditure stayed modest and left free cash flow near $260.0 million. That generation funded the Vivasure purchase and a full year of repurchases, and still let the company retire the maturing notes with cash on hand plus a revolver draw. Inventory shrank as divested product left the balance sheet, receivables carry a tight two month sales cycle, and working capital became a source of cash rather than a sink. The conversion surge reflects two forces stacking, the annuity-like disposable revenue of the hospital portfolio and the release of inventory and receivables tied to divested and deflated product lines.
The first quarter of fiscal 2027 confirmed that the reset is complete and that growth has returned across both reportable segments. Revenue rose 5.6 percent while diluted earnings per share gained despite a tax rate inflated by stock compensation shortfalls, an effect management labels discrete in origin. Per share economics held up under that tax headwind because operating income growth outran the rate jump. Apheresis grew 5.3 percent on plasma franchise gains with share growth, MedSurg grew six percent on market expansion, and gross margin held at 59.8 percent. The rebound validates the reading that fiscal 2026 declines were a transition artifact rather than erosion of the underlying franchises. MedSurg operating income rose sharply even as its revenue grew moderately, confirming that the fiscal 2026 pricing and mix actions carry through to profit, and the segment structure the company now reports makes that divergence visible for the first time.
The November CSL disclosure is the fulcrum event for the forward curve. The agreement is deliberately non-exclusive and carries no minimum purchase commitments, and management left its fiscal 2027 guidance unchanged, which is the conservative reading of a contract whose economics depend on how many of hundreds of collection centers convert and at what pace. The upside mechanism runs through consumables, since every conversion of a CSL center onto NexSys PCS with Persona PLUS creates a razor-razorblade annuity whose yield advantage gives the fractionator a measurable return on switching. Revenue of that type also compounds defensively, because disposables revenue attached to installed hardware sustains itself through industry cycles that would otherwise expose a pure capital equipment seller. The update promised at the November earnings report is where deliberate vagueness either becomes a quantified revenue stream or fades into an option. The mechanism deserves spelling out for anyone modeling it, because a fractionator adopts a collection platform only after its operations teams validate throughput and donor experience, and once those pilots clear, the disposables stream follows the installed machines for years without renegotiation.
Litigation forms the second forward lever. The company sued Terumo BCT in Colorado and then Fresenius Kabi and Fenwal in Illinois over its donor-centric plasma collection patents, and every inter partes and post grant review petition Terumo filed at the patent office was denied, leaving the district court track alive. Fenwal answered with counterclaims alleging invalidity and infringement alongside inequitable conduct accusations, so the road is long and the fees are real, but the endgame is a licensing annuity or a market-structure check on the two competitors now pressing hardest against the plasma franchise. The patents cover the exact yield features the Persona and YES clearances monetize, which is why the IP has economic weight rather than decorative value. Filing suit against two of the largest equipment rivals at once is an aggressive posture for a company of this revenue scale, but the patent office denials of every invalidity petition reduced the risk that the assertions collapse at the merits stage.
Execution risk concentrates in three places. The PerQseal Elite premarket approval decision is the immediate regulatory gate, since the large bore closure market is where structural heart procedure growth lives, and a denial or a request for more clinical work would idle a fresh $164.4 million purchase price. The ERP cutover remains multiyear and the company lost two consecutive years of leverage efficiency to migration friction, a tax on execution that is common at this scale but worth watching. Tariff exposure adds cost risk on imported components, and the fiscal 2026 expense lines already absorbed tariff impacts alongside freight and personnel inflation in services and administrative costs. The company manufactures consumables largely in North America and Malaysia with contract manufacturing spread across Asia, so the exposure is real but narrower than for device makers concentrated in single jurisdictions.
The debt stack shapes how much of the upside shareholders keep. Net debt sits just under a billion against roughly $223.4 million of cash after the first quarter, and the notes come due in mid-2029, so the refinancing problem sits in the middle rather than the end of the decade. The company already repaid $50.0 million on the revolver in the first quarter and another $50.0 million in the second. The repayment record suggests modest deleveraging without constraining the buyback, though this remains a bet on stable free cash conversion rather than a contractual promise. The convertible structure adds a second, quieter lever, because the capped call overlay offsets dilution on any conversion up to the cap price, which effectively raises the price at which dilution begins and protects the compounding math behind the buyback.
The clearest downside path runs through plasma concentration. A volume reduction, a per-unit price reset or a competitor displacing the installed platform at a major network would put a low-teens revenue percentage back into play, and the CSL episode proved the mechanism is real rather than theoretical. NexSys PCS with Persona PLUS is the strongest yield product in the market, yet purchasing committees at fractionators have shown they weigh switching costs against capital cycle timing, and a single large conversion event can erase two years of share gains in one budget cycle. The recent agreement cuts that probability at the largest account, but it does not eliminate the structural exposure, since the contract is non-exclusive and the buyer retains freedom to run a dual-supply posture indefinitely. The geographic spread of smaller accounts remains a partial offset, since no other single buyer approaches the weight of the largest relationship.
Regulatory and approval risk clusters in MedSurg. The esophageal protection franchise already absorbed a $77.2 million impairment because pulse field ablation changed clinical practice, and the same market dynamic keeps pressure on the product line even with the VASCADE MVP XL label expansion selling into sheath sizes favored by ablation equipment. PerQseal Elite carries binary approval risk, and the Interventional Technologies reporting unit holds only a six percent fair value cushion above carrying value, so a growth-path downgrade or a discount rate shift could trigger a goodwill impairment on top of the intangible charges already taken.
Balance sheet risk is real though well-contained by covenant math. The $700.0 million of convertible notes are not currently convertible, and the capped call structure offsets dilution up to a $180.18 cap, but a stressed scenario in which the notes convert after a stock decline would hand the ledger a fresh share overhang, and holders can also demand repurchase upon a fundamental change in control. Interest expense carried a meaningful drag in fiscal 2026 and the term loan carries an effective rate near the mid-five percent area, so refinancing conditions in 2029 are a genuine variable rather than a background item.
The counterargument to the bull case deserves explicit statement. The bears argue that fiscal 2026 gross margin gains are a mix illusion created by wrapping an impaired esophageal business and divested whole blood products into a smaller denominator, that the CSL agreement without minimums is a windfall claim not yet booked rather than booked revenue, and that customer concentration plus a net leverage position above three times make the equity a leveraged claim on goodwill rather than a durable compounder. That reading is internally consistent, but it fails on the most recent quarter, where growth resumed with margins held, and on the supply agreement itself, since fractionators rarely reengage a defected vendor to evaluate a fresh yield system unless the clinical case clears. The strongest version of the bear argument is the timeline, because a non-exclusive agreement presentable as an option can sit dormant for years, and a skeptic is entitled to note that the market has underwritten similar academic reengagements before without seeing volume follow.
The valuation framework starts with earnings quality because headline and economic earnings diverge sharply here. Reported diluted earnings in fiscal 2026 carried a heavy load of nonoperating charges, led by the intangible impairments and the ERP migration costs, so an adjusted figure for the year sits near $4.10 per share. Fiscal 2025 restates under that same method to a figure near $4.58, while trailing GAAP results sum to well below the adjusted number on a per share basis. The multiple a buyer pays therefore depends heavily on which earnings definition counts. Choosing the adjusted lens is not generosity, because every excluded item this year was a recognized accounting charge rather than a cash cost hidden in operations. The gap between the lenses is the valuation debate in miniature, since a buyer who capitalizes the adjusted number and a buyer who capitalizes the reported number can look at the same share price and disagree on the entire thesis.
The share price into early September sits just above the $106.31 mark, and the trailing reported multiple lands near 37 times GAAP earnings on that quote. The fiscal 2026 adjusted multiple lands near 26 times the same price. The consensus forward multiple on expected fiscal 2027 adjusted earnings sits near 18.5 times. Enterprise value near $5.8 billion prices the company at roughly 16 times reported EBITDA, a figure that absorbs the impairment drag on its own, so the cash flow lens runs markedly cheaper than the earnings optics suggest. Each lens answers a different question, which is why the cases below fix an earnings definition before picking a multiple. Multiples this compressed relative to medtech peers are rare for a franchise with plasma economics this steep, and the market is effectively paying today for the collection business while optioning the hospital compounder at little explicit cost. That framing, rather than any single multiple, is the cleanest statement of where the disagreement between bulls and bears actually lives. Free cash flow near the quarter billion mark prices the enterprise at roughly a fifth of its value in unlevered cash generation each year.
The bear, base and bull cases quantify cleanly from those inputs. The bear case assumes the CSL agreement stays economically empty, plasma revenue keeps eroding and MedSurg stalls, compressing adjusted earnings toward $3.30 per share. Applying an 18 times multiple to that figure and subtracting the net debt carried per share implies a share value in the low $40s. The base case assumes modest constant currency growth, margin stability near the 59 percent gross level, roughly a hundred million per year of continued repurchase and further revolver paydown, which holds adjusted earnings near $4.10 per share. A 31 times multiple on that earnings level, reduced by the same net debt drag, lands almost exactly on the current quote near $106.31. The base case is deliberately mechanical, because the point of the exercise is that today's price already embodies modest success, and the risk asymmetry therefore lives in the tails rather than in the center of the distribution.
The bull case gives the September agreement real economics. If CSL converts a meaningful subset of its collection network over eighteen months, plasma revenue swings to growth and the yield premium supports pricing, while PerQseal Elite approval pushes interventional growth positive and MedSurg keeps compounding at high single digits. That path lifts adjusted earnings toward $4.75 per share and earns a richer 34 times multiple against peers compounding at a similar pace. Applying that multiple and the same net debt adjustment implies share value near $140.0, roughly a third above the current quote before assigning any value to the litigation. The downside structure balances that upside, since the cash position and the revolver offset most of the debt and leave the equity cushion intact even in a stagnation scenario. That cushion is the practical meaning of the leverage stack, since a stagnation scenario at this cash level is a flat equity rather than a solvency event, a profile that suits a patient holder better than a momentum trader. Capital return authority near $325.0 million is nearly a seventh of the market capitalization, and the board has historically spent its authorizations rather than letting them lapse.
The judgment, on the evidence as of early September 2026, is that Haemonetics is a self-repairing medtech franchise at a fair rather than generous price, with the burden of proof now sitting on the November CSL quantification and the PerQseal approval window. The fiscal 2026 impulse was a mix reset forced by a giant client defection and a failed market assumption in esophageal protection, and the company answered with a gross margin step change, restored free cash flow, deleveraging and a reinvented product cycle in the segments it chose to fund. That is a real execution record, not a promise. The distinction matters because the market has repriced the fiscal 2026 damage already, and what remains uncertain is the slope of the recovery rather than its direction.
The structural cast is favorable in ways the bear case concedes too easily. Plasma collection economics reward yield per donation, and the company owns the leading yield technology stack on both device and software sides, with litigation that reinforces the moat rather than merely defends it. The MedSurg mix is now near half of revenue and its blood management lines grow at double digit rates with share gains, while the interventional reset through impairment actually removed the earnings risk that the old forecast carried. Taken together the asset base now leans toward the two things mid-cap medtech buyers pay premiums for, installed annuity revenue and procedure-linked device growth, instead of the aging collection hardware markets that used to cap the growth profile. Compounding through buybacks executed at prices below the current quote adds a low risk accretion lever to a business already compounding at the operating line.
The unresolved risks are concentration, conversion and the pace of MedSurg repair, and each is specific rather than vague. A single fractionator network controls a mid-teens revenue slice, the converts create a dilution ceiling at $180.18 through their capped calls, and the interventional unit sits six percent above its goodwill headroom, so the margin for execution error is thinner than the margin for complacency suggests. These are monitored items rather than crisis signals, and the first quarter evidence on both fronts was favorable. The discipline is to treat each as a trigger with a threshold rather than a worry without a date, because concentration has an observable quarterly print, conversion has a bankruptcy-remote maturity schedule, and the interventional cushion has a published fair value estimate that updates annually.
The final read is constructive but disciplined. At the multiple the base case earns, the stock already pays for mid single digit growth with margin stability, so new money enters on the CSL economics and the large bore approval rather than on the historical record, which the price already capitalizes. An investor holding the shares owns a business with durable plasma economics and a growing hospital engine carried on a modestly levered balance sheet, and the appropriate posture is to size for a wide range of outcomes around a base case that now has early tangible support. The November quantification is the honest test of that support, and until it lands the prudent reading treats the plasma repair as probable rather than booked, which is exactly how the current price frames it.